JILIN CHANGLONG News

Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year

BreakingsMay 13 20:05

The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years

Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.

券商中國May 12 20:03

Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve

BreakingsMay 7 01:11

JILIN CHANGLONG To Go Ex-Dividend On June 18th, 2024 With 0.06888 HKD Special Dividend Per Share

April 26th - $JILIN CHANGLONG(08049.HK)$ is trading ex-dividend on June 18th, 2024. Shareholders of record on June 19th, 2024 will receive 0.06888 HKD special dividend per share on July 16th, 2024

Futu NewsApr 26 04:05

Jilin Changlong Pharmaceutical (08049) will pay a special dividend of 0.0625 yuan per share on July 16

Jilin Changlong Pharmaceutical (08049) announced that the company will pay a special dividend per share on July 16, 2024...

Zhitong FinanceApr 25 09:59

吉林長龍藥業：宣派及派付特別股息及 暫停辦理股份過戶登記手續

Futu NewsApr 25 09:48 · Announcements

吉林長龍藥業：董事會會議通告及建議宣派及派付特別股息

Futu NewsApr 15 06:40 · Announcements

Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%

BreakingsApr 10 22:15

Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction

① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.

cls.cnApr 10 09:19

Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks

Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.

cls.cnApr 9 01:33

Multiple arrows in unison! Pharmaceutical innovation support policies are coming

Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.

cls.cnApr 8 09:34

Jilin Changlong Pharmaceutical (08049) announced annual results. Profit attributable to shareholders of 148 million yuan decreased by 23.43% year-on-year

Jilin Changlong Pharmaceutical (08049) announced results for the year ended December 31, 2023, and the group obtained revenue...

Zhitong FinanceMar 28 22:28

JILIN CHANGLONG: ANNUAL REPORT 2023

Futu NewsMar 28 09:36 · Announcements

JILIN CHANGLONG: 2023 ANNUAL RESULTS ANNOUNCEMENT

Futu NewsMar 28 09:32 · Announcements

Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?

① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?

cls.cnMar 24 21:47

JILIN CHANGLONG: NOTICE OF BOARD MEETING

Futu NewsMar 18 05:57 · Announcements

Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?

The path to the rise of innovative drugs doesn't seem easy!

券商中國Mar 13 22:50

Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?

① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.

cls.cnMar 13 20:42

Jilin Changlong Pharmaceutical (08049.HK): subscribed to 100 million yuan structured deposit products from ICBC

Gelonghui March 12, 丨 Jilin Changlong Pharmaceutical (08049.HK) issued an announcement. On March 12, 2024, the company subscribed to structured deposit products from the Industrial and Commercial Bank of China for an amount of RMB 10 million.

Gelonghui FinanceMar 12 04:27

Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”

BreakingsMar 11 20:55